Poseida Therapeutics, Inc.
PSTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | 0.00 | 1.40 | -2.57 |
| FCF Yield | -31.43% | -8.05% | -24.84% | -20.33% |
| EV / EBITDA | -3.15 | -7.09 | -2.38 | -4.23 |
| Quality | ||||
| ROIC | -58.09% | -19.52% | 2.09% | 0.68% |
| Gross Margin | -142.29% | 96.03% | -14,472.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.42 | 0.82 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,174.72% | – | – | – |
| Free Cash Flow Growth | -210.25% | 70.81% | 19.24% | -87.27% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | -0.13 | 1.24 | 0.17 |
| Interest Coverage | -14.94 | -9.41 | -42.11 | -36.09 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.16 | 0.00 | 0.00 |
| Cash Conversion Cycle | 43.22 | 183.25 | -718.53 | -107.69 |